On May 14, 2024, Oxehealth announced it received FDA 510(k) clearance for its contactless patient monitoring platform, Oxevision.
About Oxevision
Oxevision is sleep monitoring software that assesses video footage collected by a camera. It is an activity monitor designed to document and analyze physical movements, then extract information about sleep parameters based on these movements and physiological data.
By assessing video footage collected from off-the-shelf cameras installed near the bed space, algorithms derive data on bed occupancy and sleep state. The device provides a timeline of periods when the bed is occupied and when the patient is asleep.
According to the FDA approval letter, the Oxevision device software automates recognition of sleep periods, generation of sleep reports and graphical presentation for use by a health care professional.
Oxevision is designed to be used in an inpatient setting, with the cameras installed within single-occupancy bed spaces in hospitals, general care or secured environments. In the company’s press release, Oxehealth positions the Oxevision device as a patient monitoring platform for acute mental health, specifically highlighting its utility in inpatient psychiatric settings.
Oxevision is intended for use by adults aged 18 and older and is available by prescription only.
Read more industry news from the AASM.
